Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Go back to Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis| Nektar Therapeutics (NASDAQ: NKTR) | Delayed: 67.00 +0.16 (0.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $66.84 | 52 Week High | $19.98 | |||
| Open | $67.08 | 52 Week Low | $10.52 | |||
| Day High | $67.26 | P/E | N/A | |||
| Day Low | $66.25 | EPS | $-1.45 | |||
| Volume | 25,358 | |||||
